162 related articles for article (PubMed ID: 37897593)
1. Combination of Selenite and Butyrate Enhances Efficacy Against Colon Cancer by Targeting ASCT2-Mediated Amino Acid Metabolism.
Cui J; Li J; Zhao S; Fan L; Yin S; Zhao C; Hu H
Biol Trace Elem Res; 2024 Aug; 202(8):3565-3573. PubMed ID: 37897593
[TBL] [Abstract][Full Text] [Related]
2. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
3. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
[TBL] [Abstract][Full Text] [Related]
5. Superior inhibitory efficacy of butyrate over propionate and acetate against human colon cancer cell proliferation via cell cycle arrest and apoptosis: linking dietary fiber to cancer prevention.
Zeng H; Hamlin SK; Safratowich BD; Cheng WH; Johnson LK
Nutr Res; 2020 Nov; 83():63-72. PubMed ID: 33017771
[TBL] [Abstract][Full Text] [Related]
6. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAF
Schulte ML; Hight MR; Ayers GD; Liu Q; Shyr Y; Washington MK; Manning HC
Mol Imaging Biol; 2017 Jun; 19(3):421-428. PubMed ID: 27770401
[TBL] [Abstract][Full Text] [Related]
7. Butyrate Inhibits Cancerous HCT116 Colon Cell Proliferation but to a Lesser Extent in Noncancerous NCM460 Colon Cells.
Zeng H; Taussig DP; Cheng WH; Johnson LK; Hakkak R
Nutrients; 2017 Jan; 9(1):. PubMed ID: 28045428
[TBL] [Abstract][Full Text] [Related]
8. Butyrate-mediated acquisition of chemoresistance by human colon cancer cells.
Kang HR; Choi HG; Jeon CK; Lim SJ; Kim SH
Oncol Rep; 2016 Aug; 36(2):1119-26. PubMed ID: 27277338
[TBL] [Abstract][Full Text] [Related]
9. Lobetyolin induces apoptosis of colon cancer cells by inhibiting glutamine metabolism.
He W; Tao W; Zhang F; Jie Q; He Y; Zhu W; Tan J; Shen W; Li L; Yang Y; Cheng H; Sun D
J Cell Mol Med; 2020 Mar; 24(6):3359-3369. PubMed ID: 31990147
[TBL] [Abstract][Full Text] [Related]
10. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
11. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells.
Encarnação JC; Pires AS; Amaral RA; Gonçalves TJ; Laranjo M; Casalta-Lopes JE; Gonçalves AC; Sarmento-Ribeiro AB; Abrantes AM; Botelho MF
J Nutr Biochem; 2018 Jun; 56():183-192. PubMed ID: 29587241
[TBL] [Abstract][Full Text] [Related]
12. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
13. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds.
Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C
J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.
Hassanein M; Hight MR; Buck JR; Tantawy MN; Nickels ML; Hoeksema MD; Harris BK; Boyd K; Massion PP; Manning HC
Mol Imaging Biol; 2016 Feb; 18(1):18-23. PubMed ID: 25971659
[TBL] [Abstract][Full Text] [Related]
15. NEDD4L downregulates autophagy and cell growth by modulating ULK1 and a glutamine transporter.
Lee DE; Yoo JE; Kim J; Kim S; Kim S; Lee H; Cheong H
Cell Death Dis; 2020 Jan; 11(1):38. PubMed ID: 31959741
[TBL] [Abstract][Full Text] [Related]
16. A Glutamine-Rich Carrier Efficiently Delivers Anti-CD47 siRNA Driven by a "Glutamine Trap" To Inhibit Lung Cancer Cell Growth.
Wu J; Li Z; Yang Z; Guo L; Zhang Y; Deng H; Wang C; Feng M
Mol Pharm; 2018 Aug; 15(8):3032-3045. PubMed ID: 29939755
[TBL] [Abstract][Full Text] [Related]
17. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon.
Thangaraju M; Cresci GA; Liu K; Ananth S; Gnanaprakasam JP; Browning DD; Mellinger JD; Smith SB; Digby GJ; Lambert NA; Prasad PD; Ganapathy V
Cancer Res; 2009 Apr; 69(7):2826-32. PubMed ID: 19276343
[TBL] [Abstract][Full Text] [Related]
18. Physical and functional interactions between the serotonin transporter and the neutral amino acid transporter ASCT2.
Seyer P; Vandermoere F; Cassier E; Bockaert J; Marin P
Biochem J; 2016 Jul; 473(13):1953-65. PubMed ID: 27143784
[TBL] [Abstract][Full Text] [Related]
19. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells.
Hu S; Liu L; Chang EB; Wang JY; Raufman JP
Mol Cancer; 2015 Oct; 14():180. PubMed ID: 26463716
[TBL] [Abstract][Full Text] [Related]
20. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
